102 related articles for article (PubMed ID: 1382341)
1. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.
Vasudevachari MB; Battista C; Lane HC; Psallidopoulos MC; Zhao B; Cook J; Palmer JR; Romero DL; Tarpley WG; Salzman NP
Virology; 1992 Sep; 190(1):269-77. PubMed ID: 1382341
[TBL] [Abstract][Full Text] [Related]
2. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
Dueweke TJ; Poppe SM; Romero DL; Swaney SM; So AG; Downey KM; Althaus IW; Reusser F; Busso M; Resnick L
Antimicrob Agents Chemother; 1993 May; 37(5):1127-31. PubMed ID: 7685995
[TBL] [Abstract][Full Text] [Related]
3. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK
FEBS Lett; 1995 Feb; 359(2-3):233-8. PubMed ID: 7532595
[TBL] [Abstract][Full Text] [Related]
5. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.
Romero DL; Busso M; Tan CK; Reusser F; Palmer JR; Poppe SM; Aristoff PA; Downey KM; So AG; Resnick L
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8806-10. PubMed ID: 1717988
[TBL] [Abstract][Full Text] [Related]
6. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
[TBL] [Abstract][Full Text] [Related]
7. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
8. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
Olmsted RA; Slade DE; Kopta LA; Poppe SM; Poel TJ; Newport SW; Rank KB; Biles C; Morge RA; Dueweke TJ; Yagi Y; Romero DL; Thomas RC; Sharma SK; Tarpley WG
J Virol; 1996 Jun; 70(6):3698-705. PubMed ID: 8648704
[TBL] [Abstract][Full Text] [Related]
9. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha.
Pagano PJ; Chong KT
J Infect Dis; 1995 Jan; 171(1):61-7. PubMed ID: 7528253
[TBL] [Abstract][Full Text] [Related]
10. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
12. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
Nunberg JH; Schleif WA; Boots EJ; O'Brien JA; Quintero JC; Hoffman JM; Emini EA; Goldman ME
J Virol; 1991 Sep; 65(9):4887-92. PubMed ID: 1714522
[TBL] [Abstract][Full Text] [Related]
13. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
Schinazi RF; Lloyd RM; Nguyen MH; Cannon DL; McMillan A; Ilksoy N; Chu CK; Liotta DC; Bazmi HZ; Mellors JW
Antimicrob Agents Chemother; 1993 Apr; 37(4):875-81. PubMed ID: 7684216
[TBL] [Abstract][Full Text] [Related]
14. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
15. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Maass G; Immendoerfer U; Koenig B; Leser U; Mueller B; Goody R; Pfaff E
Antimicrob Agents Chemother; 1993 Dec; 37(12):2612-7. PubMed ID: 7509144
[TBL] [Abstract][Full Text] [Related]
16. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.
Esnouf RM; Ren J; Hopkins AL; Ross CK; Jones EY; Stammers DK; Stuart DI
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3984-9. PubMed ID: 9108091
[TBL] [Abstract][Full Text] [Related]
17. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
[TBL] [Abstract][Full Text] [Related]
19. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
De Clercq E
Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
Joshi P; Prasad VR
J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
